These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23409379)

  • 1. QT prolongation: a critical adverse effect of some medications.
    DeDea L
    JAAPA; 2013 Feb; 26(2):11. PubMed ID: 23409379
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced QT prolongation.
    Michowitz MK; Michowitz Y; Zaidenstien R; Golik A
    Isr Med Assoc J; 2000 Dec; 2(12):924-8. PubMed ID: 11344777
    [No Abstract]   [Full Text] [Related]  

  • 4. Drugs, QT interval abnormalities and ventricular arrhythmias.
    Thomas SH
    Adverse Drug React Toxicol Rev; 1994; 13(2):77-102. PubMed ID: 7918900
    [No Abstract]   [Full Text] [Related]  

  • 5. [Practical ECG problems in the elderly patient. Case number 16. Moxifloxacin-associated QT interval prolongation].
    Farhoumand AD; Trombert V; Eusebio J
    Rev Med Suisse; 2011 Mar; 7(286):624-5. PubMed ID: 21510347
    [No Abstract]   [Full Text] [Related]  

  • 6. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.
    Haverkamp W; Breithardt G; Camm AJ; Janse MJ; Rosen MR; Antzelevitch C; Escande D; Franz M; Malik M; Moss A; Shah R
    Eur Heart J; 2000 Aug; 21(15):1216-31. PubMed ID: 10924311
    [No Abstract]   [Full Text] [Related]  

  • 7. First report of metronidazole-induced QT interval prolongation.
    Cohen O; Saar N; Swartzon M; Kliuk-Ben-Bassat O; Justo D
    Int J Antimicrob Agents; 2008 Feb; 31(2):180-1. PubMed ID: 18082376
    [No Abstract]   [Full Text] [Related]  

  • 8. Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomes.
    Sander GE; Guillory GS; Giles TD
    Am J Geriatr Cardiol; 2002; 11(3):197-202. PubMed ID: 11986537
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacologic agents inducing electrocardiac conduction delays.
    Abdulla R
    Pediatr Cardiol; 1997; 18(3):196. PubMed ID: 9142706
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units.
    Armahizer MJ; Seybert AL; Smithburger PL; Kane-Gill SL
    J Crit Care; 2013 Jun; 28(3):243-9. PubMed ID: 23312127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [QTc-prolonging drugs and the risk of sudden death].
    Reingardiene D; Vilcinskaite J
    Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced QT prolongation and sudden death.
    Del Rosario ME; Weachter R; Flaker GC
    Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine.
    Letsas KP; Sideris A; Kounas SP; Efremidis M; Korantzopoulos P; Kardaras F
    Int J Cardiol; 2006 May; 109(2):273-4. PubMed ID: 15935493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QTc prolongation and haloperidol: just how risky is this drug?
    Howland RH
    Psychosomatics; 2014; 55(6):741-2. PubMed ID: 25497511
    [No Abstract]   [Full Text] [Related]  

  • 15. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
    Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R
    Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs and ECG changes.
    Gohal DR; Oza JJ
    J Assoc Physicians India; 1995 Jan; 43(1):68. PubMed ID: 9282650
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-induced long QT syndrome in women.
    Li G; Cheng G; Wu J; Zhou X; Liu P; Sun C
    Adv Ther; 2013 Sep; 30(9):793-802. PubMed ID: 24085659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consideration of the JT interval rather than the QT interval.
    Salik J; Muskin PR
    Psychosomatics; 2013; 54(5):502. PubMed ID: 24034531
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.
    Frommeyer G; Eckardt L
    Nat Rev Cardiol; 2016 Jan; 13(1):36-47. PubMed ID: 26194552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.